CYGENICA LIMITED

CyGenica Limited is a cutting‑edge biotechnology company dedicated to overcoming the long‑standing barriers of intracellular drug delivery. Their flagship innovation, GEENIE, is an engineered protein nanoneedle that penetrates cells without relying on endosomal pathways, allowing therapeutic molecules—ranging from nucleotides to full‑size proteins—to reach their intracellular targets with essentially 100 % efficiency. By sidestepping the low delivery rates and toxicity issues that plague conventional systems, GEENIE opens new avenues for treating cancers and rare disorders that currently lack effective therapies.

The company’s expertise lies in the design and optimisation of protein chimeras for precise therapeutic delivery, supported by collaborations with leading academic researchers in fields such as computational modelling of neurotoxicity and whole‑animal imaging for biodistribution studies. CyGenica’s platform is aimed at biopharmaceutical partners seeking to enhance the potency and safety of advanced therapeutics, offering a transformative solution that can reshape the future of intracellular medicine.